SLRX Profile
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology firm based in Houston, Texas, specializes in developing novel cancer therapies based on epigenetic mechanisms. The company is at the forefront of innovation in cancer treatment, focusing on drugs that target the epigenetic modifications associated with cancer progression. Founded with a commitment to addressing the significant unmet needs in oncology, Salarius aims to leverage its proprietary technologies to offer new treatment options for patients with difficult-to-treat cancers.
The company's leading candidate, Seclidemstat (SP-2577), is a small molecule inhibitor currently undergoing Phase I/II clinical trials. This investigational drug targets lysine-specific demethylase 1 (LSD1), a protein involved in the regulation of gene expression linked to cancer development. SP-2577 is being evaluated for its efficacy in treating advanced solid tumors, including Ewing sarcoma, a rare and aggressive form of cancer. The drug's potential to inhibit cancer cell growth through epigenetic modulation positions it as a promising candidate in the oncology pipeline.
In addition to Seclidemstat, Salarius is developing SP-3164, another small molecule designed to degrade specific proteins implicated in hematological and solid tumors. SP-3164 represents a novel approach to cancer therapy by targeting and degrading proteins that drive tumor growth and resistance. This compound is part of Salarius' broader strategy to create a diverse portfolio of epigenetic-based treatments.
Salarius has established several strategic partnerships to advance its research and development efforts. It holds an exclusive license agreement with The University of Utah Research Foundation for patent rights related to SP-2577 and its analogs. The company has also partnered with HLB Life Sciences for the development, production, and commercialization of SP-2577 in South Korea, and collaborates with the Cancer Prevention and Research Institute of Texas for product development activities. Additionally, Salarius works with the Cancer Epigenetics Institute at Fox Chase Cancer Center to explore new indications and biomarkers for SP-2577, demonstrating its commitment to advancing cancer research and improving patient outcomes.
|
